# Origingene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/origingene

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $1.4M
- Latest round: Angel (Dec 31, 2024)
- Investors on record: 2

## About

Founded in 2019 and based in Shanghai, China, Origingene operates as a biotechnology company that focuses on the research and development of clinical diagnostic technologies. It was recognized as the National High-tech Enterprise. The company has 12 software copyrights. In July 2024, Origingene closed a strategic investment from new investors HY Capital and Shanghai Yijian Biomedical Technology. In December 2024, the firm raised over CNY 10 million in angel funding.

The company's main business includes scientific research services and clinical testing. It provides services related to the development and transformation of clinical diagnostic technologies. The company has developed several original technologies in the fields of NGS and isothermal amplification. It built multiple tumor and pathogenic microbial databases.

The company generates revenue by providing clinical diagnostic technologies and related services.

The company will use the angel funding for product development related to overall solutions for detecting unknown pathogens in pets and veterinary medicine.

## Funding rounds

- Angel, Dec 31, 2024, $1.4M — HY Capital, Jiaxing Guangrun Equity Investment Fund Management

## Investors

- HY Capital (https://capitalatlas.ai/funds/hy-capital) — Angel
- Jiaxing Guangrun Equity Investment Fund Management — Angel